Eurofins Scientific SE
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
€11.00 | Rttfr | Rcrlgwh |
Eurofins Earnings: Revenue Growth Aids Post-COVID-19 Rebound, Some Macroeconomic Headwinds Remain
Eurofins’ third-quarter results were roughly as expected with steady top-line growth, as the period of COVID-19-related sales drag has ended. Our fair value estimate remains unchanged, as cash flows generated since our last valuation update are largely offset by marginal adjustments to our near-term assumptions to reflect recent trends and management’s reiterated full-year 2023 guidance. Shares currently look undervalued, providing a potential opportunity to invest in what we see as a solid, narrow-moat business with global market-leading positions and sound investment strategies.